Mode of action of the novel phenazine anticancer agents XR11576 and XR5944

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 139-148

  Lewis, Louisa J ^a   Mistry, Prakash ^b,d   Charlton, Peter A ^b,c   Thomas, Hilary ^a   Coley, Helen M ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b Cantab Pharmaceuticals Ltd   (United Kingdom)

^c VERTEX PHARMACEUTICALS   (United States)

^d UCB PHARMA   (Belgium)

Author keywords

Apoptosis; Drug resistance; Dual topoisomerase I II poisons

Indexed keywords

CAMPTOTHECIN; DEOXYRIBONUCLEOPROTEIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; LIPOCORTIN 5; PHENAZINE DERIVATIVE; TARIQUIDAR; XR 11576; XR 5944;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOSTASIS; CYTOTOXICITY TEST; DNA CONTENT; DNA CROSS LINKING; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BCL-X PROTEIN; BLOTTING, WESTERN; CAMPTOTHECIN; CASPASE 9; CELL CYCLE; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; INDICATORS AND REAGENTS; NEOPLASM PROTEINS; PHENAZINES;

EID: 33845718428     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328010772f     Document Type: Article

References (28)

1. Chen S, Gomez SP, McCarley D, Mainwaring MG. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol 2002; 49:347-355.
2. Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res 1997; 57:1425-1428.
3. Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, et al. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma 2002; 43:1581-1587.
4. Hammond LA, Eckardt JR, Ganapathi R, Burris HA, Rodriguez GA, Eckhardt SG, et al. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res 1998; 4:1459-1467.
5. Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C. Topotecan and etoposide as a first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen. Lung Cancer 2005; 48:409-413.
6. Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, et al. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Cancer 1997; 76:1494-1499.
7. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 1987; 30:664-669.
8. Padget K, Stewart A, Charlton PA, Tilby MJ, Austin CA. An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukemia cells. Biochem Pharmacol 2000; 60:817-821.
9. Minderman H, Wrzosek C, Utsugi SCT, Kobunai T, Yamada Y, Rustum YM. Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemother Pharmacol 2000; 45:78-84.
10. Etieviant C, Kruczynski A, Barret JM, Perrin D, Hill BT. Apoptotic cell death induction by F11782 a novel dual catalytic inhibitor of topoisomerases I and II. Biochem Pharmacol 2003; 65:755-763.
11. Stewart AJ, Mistry P, Dangerfield W, Bootle D, Baker M, Koefler B, et al. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs 2001; 12:359-367.
12. Mistry P, Stewart AJ, Dangerfield W, Baker M, Liddle C, Bootle D, et al. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs 2002; 13:15-28.
13. Jobson A, Willmore E, Tilby M, Mistry P, Charlton P, Austin C. Characterisation of the roles of topoisomerase I and II in the mechanism of action of novel anti-tumour agents XR11576 (MLN576) and XR5944 (MLN944). Eur J Cancer 2002; 38:S31.
14. Finlay GJ, Riou JF, Baguley BC. From amsacrine to DACA 9N-[2- (dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 1996; 32A:708-714.
15. Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connelly K, Reimer C, et al. Biological characterization of MLN944: a potent DNA binding agent. Mol Cancer Ther 2004; 3:47-58.
16. Dai J, Punchihewa C, Mistry P, Ooi AT, Yang D. Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug. J Biol Chem 2004; 279:46096-46103.
17. Fleming JA, Blackman RK, Thoroddsen V, Ruldolph-Owen L, Charlton PA, Bulawa C. Using yeast to probe the mechanism of action of MLN944 (XR5944), a novel bis-phenazine with potent anti-tumour activity. Proc Am Assoc Cancer Res 2003; 44:1504-1505.
18. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liggle C, Bootle D, et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 2001; 61:749-758.
19. Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987; 56:279-285.
20. Zhitovich A, Costa M. A simple, sensitive assay to detect DNA-protein crosslinks in intact cells and in vivo. Carcinogenesis 1992; 13:1485-1489.
21. Kato S, Ideguchi H, Muta K, Nishimura J, Nawata H. Mechanisms involved in the development of adriamycin resistance in human leukemic cells. Leuk Res 1990; 14:567-573.
22. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59:4559-4563.
23. Van der Zee AJG, Hollema H, de Jong S, Boonstra H, Gouw A, Willemse PHB, et al. P-glycoprotein expression and DNA topoisomerase I and II acitivity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51:5915-5920.
24. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in huma primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8:933-938.
25. Schindlbeck C, Janni W, Shabani N, Kornmeier A, Rack B, Rjosk D, et al. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and topoisomerase II alpha-status of the primary tumor? J Cancer Res Clin Oncol 2005; 131:539-546.
26. Di Nicolantonio F, Knight LA, Di Palma S, Sharma S, Whitehouse PA, Mercer SJ, et al. Ex-vivo characterization of XR11576 (MLN576) against ovarian cancer and ither solid tumors. Anticancer Drugs 2004; 15:849-860.
27. Miller CA, Cohen MD, Costa M. Complexing of actin and other nuclear proteins to DNA by cis-diamminochloroplatinum(II) and chromium compounds. Carcinogenesis 1991; 12:269-276.
28. Sawyer TE, Bonner JA. The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11. Br J Cancer 1996; 27(Suppl):S109-S113.